Home›Trial›NCT03428646
NCT03428646ACTIVE NOT RECRUITING

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

Study Summary

A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)

Conditions
Dermatitis, Atopic
Interventions / Drugs
Dupilumab
View on ClinicalTrials.gov ↗
Sponsor
REGN
Regeneron Pharmaceuticals
Antibody Therapeutics
D47/100
Study Details
Enrollment858 participants
Primary Completion—
Lead SponsorRegeneron Pharmaceuticals
Data Retrieved2026-04-11 02:55:54.866387+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 858 participants
Sponsor Catalyst Profile

Regeneron Pharmaceuticals (REGN) is the sponsoring company for this trial. BiotechSign currently grades this company D (47/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

REGN Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.